Novartis AG (ETR:NOT)
Germany
· Delayed Price · Currency is EUR 100.90
+0.36 (0.36%)
At close: Jun 20, 2025, 5:30 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Innovative Medicines | 51.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Innovative Medicines Growth | 12.13% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Sandoz | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Sandoz Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cardiovascular, Renal And Metabolic | 9.06B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cardiovascular, Renal And Metabolic Growth | 30.29% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Immunology | 9.62B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Immunology Growth | 18.48% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience | 5.04B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience Growth | 29.17% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oncology | 15.30B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Growth | 16.88% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Established Brands | 12.69B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Established Brands Growth | -11.86% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2011 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2011 - 2019 |
| Innovative Medicines Operating Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Innovative Medicines Operating Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Sandoz Operating Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Sandoz Operating Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Operating Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Operating Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Gross Income by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2011 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2011 - 2019 |
| Innovative Medicines Gross Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Innovative Medicines Gross Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Sandoz Gross Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Sandoz Gross Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Gross Profit |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Gross Profit Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| United States Revenue (Post-Q2 2023 Reporting) | 22.27B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Revenue (Post-Q2 2023 Reporting) Growth | 20.40% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Revenue (Post-Q2 2023 Reporting) | 15.70B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Revenue (Post-Q2 2023 Reporting) Growth | 3.97% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) | 10.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) Growth | 6.55% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Canada and Latin America Revenue (Post-Q2 2023 Reporting) | 3.54B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Canada and Latin America Revenue (Post-Q2 2023 Reporting) Growth | 7.57% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia/Africa/Australasia Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia/Africa/Australasia Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Canada and Latin America Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Canada and Latin America Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Gilenya Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Gilenya Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Tasigna Revenue | 1.65B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Tasigna Revenue Growth | -7.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Lucentis Revenue | 919.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Lucentis Revenue Growth | -33.07% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cosentyx Revenue | 6.35B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cosentyx Revenue Growth | 21.40% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Entresto Revenue | 8.20B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Entresto Revenue Growth | 25.92% |
Log In |
Log In |
Log In |
Log In | Upgrade
|